Holen Sie sich die Stockscreener-App
189.67
2.04%
3.7201
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$185.95
Offen:
$189.305
24-Stunden-Volumen:
162.45K
Relative Volume:
0.13
Marktkapitalisierung:
$27.83B
Einnahmen:
$9.53B
Nettoeinkommen (Verlust:
$1.29B
KGV:
21.54
EPS:
8.8057
Netto-Cashflow:
$1.97B
1W Leistung:
+5.10%
1M Leistung:
+4.56%
6M Leistung:
+28.45%
1J Leistung:
+59.59%
1-Tages-Spanne:
$188.67
$191.00
1-Wochen-Bereich:
$174.85
$191.00
52-Wochen-Spanne:
$115.25
$202.41
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
189.62 | 27.29B | 9.53B | 1.29B | 1.97B | 8.8057 |
LLY
Lilly Eli Co
|
918.20 | 806.72B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
226.93 | 544.73B | 96.36B | 21.04B | 19.70B | 8.6488 |
ABBV
Abbvie Inc
|
204.63 | 362.81B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
195.93 | 303.62B | 58.80B | 10.24B | 8.98B | 3.2788 |
NVS
Novartis Ag Adr
|
147.83 | 282.35B | 54.72B | 14.02B | 15.32B | 7.1855 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-20 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-04-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-09 | Bestätigt | H.C. Wainwright | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
UBS Upgrades Biogen to Buy From Neutral, Adjusts Price Target to $225 From $185 - marketscreener.com
Analyst recommendations: Albemarle, Biogen, Qualcomm, Twilio, Lyondellbasell… - marketscreener.com
TJ Biopharma enters into agreement with Biogen for Felzartamab assets in Greater China Region - BioSpectrum Asia
UBS upgrades Biogen stock rating on pipeline catalysts, raises target to $225 - Investing.com Canada
Stocks making big moves yesterday: Cadence Design Systems, JFrog, Lucid, Ulta, and Biogen - Yahoo Finance
Biogen Inc. Secures Global Rights To Felzartamab Through Greater China Deal With TJ Biopharma - BioPharma APAC
Biogen amasses full felzartamab rights with $850M TJ deal - BioWorld News
BIIB Inks Deal to Acquire Rights to Felzartamab in China, Stock Up - TradingView
3 Reasons to Avoid BIIB and 1 Stock to Buy Instead - Yahoo Finance
Amyloid Setback: Future Possibilities For The Treatment Of Alzheimer's Disease - Seeking Alpha
Biogen gets worldwide development and commercialization rights to felzartamab - The Pharma Letter
Lobbying Update: $1,460,000 of BIOGEN lobbying was just disclosed - Quiver Quantitative
Biogen (BIIB) Stock Trades Up, Here Is Why - Yahoo Finance
Biogen Inc (BIIB) Shares Surge 3.4% -- What GF Score of 72 Tells Investors - GuruFocus
Biogen Inc. stock (US09062X1037): Is its neurology focus strong enough to drive new upside? - AD HOC NEWS
Biogen earnings preview: What to expect - MSN
Biogen (BIIB) Secures Exclusive Rights to Felzartamab in Greater China - GuruFocus
BIIB Upgraded by Wells Fargo -- Price Target Raised to $250 - GuruFocus
Biogen Earnings Preview: What to Expect - Barchart.com
Biogen to buy China rights to immune disease drug for up to $850M - Seeking Alpha
Wells Fargo Upgrades Biogen to Overweight: Does the Alzheimer's Story Finally Have a Second Act? - 24/7 Wall St.
Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma - Reuters
TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region - Tirto.id
Biogen enters into agreement with TJ Biopharma for Felzartamab assets in the Greater China region - marketscreener.com
Biogen acquires China rights to felzartamab for up to $850M By Investing.com - Investing.com Canada
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region - Biogen
Biogen Enters Into Agreement With TJ Biopharma For Felzartamab Assets In The Greater China Region - marketscreener.com
Wells Fargo Upgrades Biogen to Overweight From Equalweight, Adjusts PT to $250 From $200 - marketscreener.com
Biogen Expands Targeted Therapy Pipeline With Apellis Deal And Alloy Alliance - Yahoo Finance
Biogen Inc. (NASDAQ:BIIB) Rating Balance Draws Nasdaq Composite Attention - Kalkine Media
Notable analyst calls this week: Tesla, Qualcomm and Biogen among top picks - Seeking Alpha
Understanding Momentum Shifts in (BIIB) - Stock Traders Daily
Biogen Inc. (NASDAQ:BIIB) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Biogen secures FDA nod for higher dose of SMA drug Spinraza - MSN
Should Value Investors Buy Biogen (BIIB) Stock? - Yahoo Finance
Biogen CEO: China will match U.S. drug innovation in five to 10 years - The Business Journals
Zacks.com featured highlights include Biogen, TE Connectivity and ZTO Express (Cayman) - The Globe and Mail
Biogen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Bulls and Biogen Team Up to Celebrate "America 250" with Triangle Community - MLB.com
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’ - BioWorld News
'There's a lot of momentum': Biogen acquisition translates into West Coast hub with immunology focus - The Business Journals
US FDA's accelerated approval for drugs needs more transparency, says research firm - marketscreener.com
How Biogen’s Alloy ASO Deal Could Shape Its Neurology Pipeline Will Impact Biogen (BIIB) Investors - simplywall.st
This Healthcare Stock Has Made Long-Term Investors Rich -- Can It Keep Doing It? - The Motley Fool
Sumitomo Mitsui Trust Group Inc. Lowers Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen (BIIB) Valuation Check After Mixed Recent Returns And Growing Focus On LEQEMBI Growth Potential - Yahoo Finance
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Piper Sandler upgrades Biogen stock rating on acquisition strength By Investing.com - Investing.com South Africa
Piper Sandler upgrades Biogen stock rating on acquisition strength - Investing.com
Biogen stock upgraded at Piper Sandler (BIIB:NASDAQ) - Seeking Alpha
Biogen Secures FDA Nod for Higher Dose of SMA Drug Spinraza - Eastern Progress
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.92%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):